There are 579 papers on SARC-F in aging research: 19 trials and 515 observational studies in people, 34 reviews.
579 papers study it201 more mention it223 findings
26 new papers in 30 daysSee all 780 papers on SARC-F
At a glance
Higher SARC-F scores are linked with mortality in human observational studies and with lower grip strength and poorer physical performance in older adults. Sarcopenia detection varies across populations and definitions. A human trial reports lower scores with a polyphenol-rich diet, leucine, cholecalciferol and magnesium added to rehabilitation.
223 findings in 157 papers from 2015 to 2026, 26 of them since April 2026
“men with SARC-F 2-3 (indicator of pre-sarcopenia) and SARC-F ≥ 4 had significantly increased risk of all-cause mortality [hazard ratio (HR) = 1.00, 1.77, 3.73, P < 0.001]”
- Human trial19
- Humans515
- In silico2
Interventions
4Nordic walking with ankle weights
downin humans1
1 study
Nordic walking with ankle weights
downin humans1
Nordic walking with ankle weights decrease SARC-F in humans (versus Nordic walking alone) (β_adj=-1.17).
“SARC-F score (β_adj=-1.17; p<0.001)”
Human trialversus Nordic walking alone12 weeksn = 36
Rehabilitacion
Polyphenol-rich diet + leucine + cholecalciferol + magnesium
downin humans1
1 study
Polyphenol-rich diet + leucine + cholecalciferol + magnesium
downin humans1
Polyphenol-rich diet + leucine + cholecalciferol + magnesium decreases SARC-F in humans (alongside rehabilitation vs rehabilitation alone) (U = 30.0, p = 0.002).
“the study group showed significantly better subjective outcomes, including lower SARC-F scores (U = 30.0, p = 0.002)”
Human trialalongside rehabilitation vs rehabilitation alone3 monthsn = 28
Life (Basel, Switzerland)
More on Polyphenol-rich diet + leucine + cholecalciferol + magnesium
COVID-19 pandemic
upin humans1
1 study
COVID-19 pandemic
upin humans1
COVID-19 pandemic increases SARC-F in humans (MD = 0.67, 95%CI = [0.41, 0.93]).
“There was a significant difference in SARC-F scores (MD = 0.67, 95%CI = [0.41, 0.93], Z = 5.00, P < .00001)”
Review
Medicine
Exercise
upin humans1
1 study
Exercise
upin humans1
Exercise improves SARC-F in humans (38.8% to 29.0%, P < 0.001).
“At baseline, 38.8% of patients were screened as at risk for sarcopenia by SARC-F. This decreased to 29.0% after the intervention (P < 0.001).”
Human trial12 weeksn = 31
JPEN. Journal of parenteral and enteral nutrition
Effects
14Mortality
no changein humans2
2 studies
Mortality
no changein humans2
SARC-F was not clearly linked with mortality in humans (older adults with cardiovascular diseases admitted to the ER).
“SARC-F was not related to mortality.”
Humansolder adults with cardiovascular diseases admitted to the ERn = 160
Journal of geriatric physical therapy (2001)
SARC-F was not clearly linked with mortality in humans (patients with metastatic cancer at high nutritional risk).
“There was no association between the risk of sarcopenia and one-year mortality in patients with metastatic cancer.”
Humanspatients with metastatic cancer at high nutritional risk
Nutrition and cancer
Appendicular lean soft tissue
no changein humans1
1 study
Appendicular lean soft tissue
no changein humans1
SARC-F was not clearly linked with appendicular lean soft tissue in humans (Kawakami-defined low muscle mass) (AUC 0.563 (95% CI 0.480-0.646)).
“SARC-F did not discriminate Kawakami-defined low muscle mass: AUC 0.563 (95% CI 0.480-0.646) in women”
HumansKawakami-defined low muscle massfemales
Clinical nutrition ESPEN
Body composition parameters
no changein humans1
1 study
Body composition parameters
no changein humans1
SARC-F was not clearly linked with body composition parameters in Hindi-speaking cancer patients (P > 0.05).
“No statistically significant correlations were observed between SARC-F scores and age, performance status, or body composition parameters (all P > 0.05).”
Humansin Hindi-speaking cancer patientsHindi translated questionnairen = 100
World journal of methodology
Functional independence
downin humans1
1 study
Functional independence
downin humans1
SARC-F is linked with lower functional independence in humans (hospitalized for hip fracture) (-2.85 points (95% CI, -3.45 to -2.24)).
“each 1-point increase in SARC-F was associated with a 2.85-point reduction in the Barthel Index (95% CI, −3.45 to −2.24; p < 0.001)”
Humanshospitalized for hip fracturen = 330
Journal of Health Sciences
Rectus femoris muscle elasticity
no changein humans1
1 study
Rectus femoris muscle elasticity
no changein humans1
SARC-F was not clearly linked with rectus femoris muscle elasticity in humans (age- and sex-adjusted) (p = 0.116).
“In the age- and sex-adjusted model, this association was no longer significant (p = 0.116).”
Humansage- and sex-adjustedn = 140
Assessing the ability of SARC-F to reflect elastography-based muscle quality in older adults
Acta clinica Belgica
Pneumonia
no changein humans1
1 study
Pneumonia
no changein humans1
SARC-F was not clearly linked with pneumonia in humans (stable schizophrenia patients aged ≥50 years).
“However, in stable schizophrenia patients with SARC-F scores ≥4 and < 4, this study has not yet observed a similar pattern for pneumonia risk.”
Humansstable schizophrenia patients aged ≥50 yearsn = 335
Heliyon
Walking time
downin humans1
1 study
Walking time
downin humans1
SARC-F is linked with lower walking time in humans (older hospitalised patients) (-0.07 h).
“For every unit increase in SARC-F, there was a 0.07 h shorter walking time upon discharge.”
Humansolder hospitalised patientsn = 31
Diminished Physical Activity in Older Hospitalised Patients with and without COVID-19
Journal of clinical medicine
Overall survival
downin humans1
1 study
Overall survival
downin humans1
SARC-F is linked with lower overall survival in humans (liver disease) (78.3% vs 90.1% (p = 0.0181)).
“The 1-year cumulative overall survival ratio in patients with SARC-F ≥ 1 (n = 159) and SARC-F 0 (n = 110) was 78.3% and 90.1% (p = 0.0181).”
Humansliver disease1-yearn = 269
Accurate SARC-F Score in Patients with Liver Disease
Diagnostics (Basel, Switzerland)
SF-36 physical functioning
downin humans1
1 study
SF-36 physical functioning
downin humans1
SARC-F is linked with lower SF-36 physical functioning in humans (cardiovascular disease and cognitive impairment) (all P < 0.001).
“Sarcopenia (SARC-F score ≥ 4 points) was associated with poorer motor function test outcomes and SF-36PF scores (all P < 0.001).”
Humanscardiovascular disease and cognitive impairmentn = 408
Experimental gerontology
T-score
no changein humans1
1 study
T-score
no changein humans1
SARC-F was not clearly linked with T-score in patients assessed after COVID-19 vs non-COVID-19.
“No correlation of the SARC F and SPPB scores with the T score values obtained by osteo-densitometry was found.”
Humansin patients assessed after COVID-19 vs non-COVID-19n = 157
The Effects of the 'Catabolic Crisis' on Patients' Prolonged Immobility after COVID-19 Infection
Medicina (Kaunas, Lithuania)
All 14Fewer
Upstream
4Age
no changein humans1upin humans1OR 1.081
2 studies
Age
no changein humans1upin humans1OR 1.081
Age was not clearly linked with SARC-F in humans (r = 0.1, p = 0.3).
“not with age (r = 0.1, p = 0.3) or BMI (r = 0.1, p = 0.4)”
Humansn = 100
Health science reports
Age is linked with higher SARC-F in humans (systemic sclerosis) (OR 1.081 (95% CI 1.012-1.154, p = 0.020)).
“A multivariate logistic regression analysis identified age as the only factor significantly influencing the SARC-F score, with an odds ratio of 1.081 (95% CI 1.012-1.154, p = 0.020).”
Humanssystemic sclerosisn = 80
Assessment of Factors Related to Sarcopenia in Patients with Systemic Sclerosis
Journal of clinical medicine
Body composition disorders
no changein humans1
1 study
Body composition disorders
no changein humans1
Body composition disorders were not clearly linked with SARC-F in patients with coronary artery disease.
“The average score on the SARC-F questionnaire did not differ significantly in the groups of patients with various BCD.”
Humansin patients with coronary artery diseasen = 720
VARIOUS BODY COMPOSITION DISORDERS IN ELDERLY PATIENTS WITH ATHEROSCLEROSIS OF VASCULAR BEDS
Complex Issues of Cardiovascular Diseases
Atrial fibrillation
upin humans1
1 study
Atrial fibrillation
upin humans1
Atrial fibrillation is linked with higher SARC-F in humans.
“Participants with AF exhibited significantly higher SARC-F and SarQol scores.”
Humans
Sarcopenia in atrial fibrillation: a prospective study
Turkish journal of medical sciences
Gastrointestinal disease type
no changein humans1
1 study
Gastrointestinal disease type
no changein humans1
Gastrointestinal disease type was not clearly linked with SARC-F in humans (gastrointestinal diseases) (17.5% in UGD, 12.0% in LGD, 17.3% in BPD, and 13.7% in LD (overall p = 0.1235)).
“The proportion of SARC-F ≥4 points in groups of UGD, LGD, BPD, and LD were 17.5% (57/326) in UGD, 12.0% (43/357) in LGD, 17.3% (72/416) in BPD, and 13.7% (25/183) in LD, respectively (overall p = 0.1235).”
Humansgastrointestinal diseasesn = 1,282
Comparison of SARC-F Score among Gastrointestinal Diseases
Journal of clinical medicine
Associations
114Sarcopenia
upin humans29downin humans3no changein humans2OR 1.447–4.788
34 studies
Sarcopenia
upin humans29downin humans3no changein humans2OR 1.447–4.788
SARC-F predicts sarcopenia in humans (AUC 0.654).
“both showed higher AUCs than SARC-F (AUC: SARC-F 0.654, SARC-CalF 0.808, CC 0.822; Figure 1).”
HumansPatients admitted for acute cardiovascular disease treatment; sarcopenia defined by AWGS 2025n = 398
ESC Congress 2026 abstract
SARC-F is linked with a higher risk of sarcopenia in humans (adjusted OR 3.34, p<0.001).
“SARC-F score ≥4 (adjusted OR 3.34)”
Humansn = 1,474
Development of a Sarcopenia Score for Sarcopenia Screening in Community-Dwelling Older Adults
Journal of the Medical Association of Thailand
SARC-F predicts sarcopenia in humans (screening possible sarcopenia) (AUC 0.67, 95% CI 0.622-0.710).
“it showed poor discriminative ability in detecting possible sarcopaenia (area under the ROC curve=0.67; 95% confidence interval=0.622-0.710; P<0.001).”
Humansscreening possible sarcopenian = 578
Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia
SARC-F predicts sarcopenia in humans (overall population) (AUC = 0.693).
“ROC analysis revealed that SARC-F had the highest diagnostic accuracy in the overall population (AUC = 0.693)”
Humansoverall populationn = 347
BMC geriatrics
SARC-F predicts sarcopenia in humans (for probable sarcopenia in patients with rheumatoid arthritis) (sensitivity 86.2%, NPV 91.3%, specificity 54.5%).
“SARC-F showed high sensitivity (86.2%) and NPV (91.3%) for probable sarcopenia but had low specificity (54.5%) and poor discrimination for confirmed (AUC: 0.43) and severe (AUC: 0.44) cases.”
Humansfor probable sarcopenia in patients with rheumatoid arthritisn = 106
Physiotherapy theory and practice
SARC-F predicts sarcopenia in humans (chronic hemodialysis) (OR 2.422, 95 % CI 1.676-3.501).
“higher baseline SARC-F scores (OR 2.422, 95 % CI 1.676-3.501) were associated with increased risk”
Humanschronic hemodialysisone yearn = 146
Journal of the Formosan Medical Association = Taiwan yi zhi
SARC-F predicts sarcopenia in humans (rheumatoid arthritis) (AUC 0.60, sensitivity 34.8%, specificity 84.5%).
“The areas under the receiver operating characteristic (ROC) curve for the SARC-F, SARC-CalF, MSRA-7, MSRA-5, and modified MSRA-5 questionnaires were 0.60, 0.74, 0.65, 0.62, and 0.65, respectively”
Humansrheumatoid arthritisn = 299
Journal of clinical medicine
SARC-F predicts sarcopenia in humans (outpatient geriatric clinics) (AUC 0.91 (95%CI: 0.86-0.95)).
“The area under the curve (AUC) was 0.91 (95%CI: 0.86-0.95).”
Humansoutpatient geriatric clinicsn = 200
BMC geriatrics
SARC-F predicts sarcopenia in humans (screening threshold ≥2) (AUC 0.77 (95% CI 0.67-0.88), sensitivity 0.78, specificity 0.75).
“A SARC-F cut point of ≥2 yielded an area under the curve of 0.77 (95% CI 0.67-0.88), with sensitivity of 0.78, specificity of 0.75”
Humansscreening threshold ≥2n = 204
JMIRx med
SARC-F predicts sarcopenia in community-dwelling older adults (AUC 0.530, sensitivity 0.07, specificity 0.99).
“In the case-finding step, the sensitivity for Scenarios1 to 4 was 0.86,0.84,0.23 and 0.07, respectively; specificity was 0.57,0.58,0.93 and 0.99, respectively; and the AUCs were 0.717,0.710,0.581 and 0.530, respectively.”
Humansin community-dwelling older adultsn = 2,453
BMC geriatrics
All 34Fewer
Mortality
upin humans15OR 1.18–8.34
15 studies
Mortality
upin humans15OR 1.18–8.34
SARC-F is associated with mortality in humans (hospitalized) (HR ranging from 3.77 to 9.47).
“Cox proportional hazards analysis revealed that a SARC-F score ≥1 was associated with significantly higher hazard ratios across all age groups (ranging from 3.77 to 9.47; all P < 0.01).”
Humanshospitalizedn = 12,743
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
SARC-F predicts mortality in humans (hospitalized) (AUC 0.721 (IQR 0.678-0.764)).
“SARC-F scores at admission had a significant area under the ROC curve (0.721, IQR 0.678-0.764; P < 0.001) for predicting mortality.”
Humanshospitalizedn = 12,743
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
SARC-F predicts mortality in humans (cancer patients at high nutritional risk) (p = 0.002).
“There was an association between sarcopenia risk and one-year mortality in all cancer patients (p = 0.002)”
Humanscancer patients at high nutritional riskn = 185
Nutrition and cancer
SARC-F predicts mortality in humans (acutely decompensated heart failure) (adjusted OR = 1.18 (CI95% 1.03–1.33), p = 0.003).
“HGS (β = -0.73 ± 0.03, p = 0.008) and SARC-F [adjusted OR = 1.18 (CI95% 1.03–1.33), p = 0.003] resulted independently associated with mortality.”
Humansacutely decompensated heart failure30 daysn = 184
Research SquarePreprint
SARC-F is linked with a higher risk of mortality in humans (older patients with cardiovascular disease) (HR 2.02 (95% CI: 1.39 – 2.92, p < 0.001)).
“A SARC-F score of 4 or higher was significantly associated with an increased risk of all-cause mortality, with HR of 2.02 (95% CI: 1.39 – 2.92, p < 0.001)”
Humansolder patients with cardiovascular disease6 monthsn = 285
Research SquarePreprint
SARC-F predicts mortality in humans (cancer) (HR = 3.1, p < 0.001).
“Incorporating SARC-F improved survival prognostication beyond SMI and SMD (HR = 3.1; p < 0.001; Harrel's C from 0.73 to 0.76).”
Humanscancern = 212
Cancer medicine
SARC-F is linked with a higher risk of mortality in humans (HR 1.6, 95% CI 1.1-2.3).
“Abnormal grip, SARC-F, and FRAIL scale assessments were associated with higher mortality risk (HR [95%CI] = 2.0 [1.4-2.9], 1.6 [1.1-2.3], 2.0 [1.4-2.8]).”
Humans
Skeletal radiology
SARC-F predicts mortality in humans (liver disease) (AUC 0.60, sensitivity 0.57, specificity 0.62).
“In the receiver operating curve (ROC) analysis based on the prognosis for the SARC-F score, the area under the ROC was 0.60.”
Humansliver diseasen = 269
Accurate SARC-F Score in Patients with Liver Disease
Diagnostics (Basel, Switzerland)
SARC-F is associated with mortality in humans (COVID-19) (34% greater risk of death, p = 0.003).
“One score greater SARC-F was associated with 34% (p = 0.003) greater risk of death”
HumansCOVID-19n = 163
BMC geriatrics
SARC-F is linked with a higher risk of mortality in humans (SARC-F score ≥ 4 vs 0-1, adjusted) (HR = 3.73, P < 0.001).
“men with SARC-F 2-3 (indicator of pre-sarcopenia) and SARC-F ≥ 4 had significantly increased risk of all-cause mortality [hazard ratio (HR) = 1.00, 1.77, 3.73, P < 0.001]”
HumansSARC-F score ≥ 4 vs 0-1, adjusted6.8 yearsmales
Prognostic utility of self-reported sarcopenia (SARC-F) in the Multiethnic Cohort
Journal of cachexia, sarcopenia and muscle
All 17Fewer
Handgrip strength
downin humans7upin humans1
8 studies
Handgrip strength
downin humans7upin humans1
SARC-F is associated with handgrip strength in humans (Subacute stroke survivors; non-affected side; adjusted for age, sex, and time since stroke) (Adjusted coefficient −5.90 kg (95% CI −11.22 to −0.59)).
“Adjusted HGS coefficients were −5.90 kg (95% CI −11.22 to −0.59; p = 0.030) for SARC-F”
HumansSubacute stroke survivors; non-affected side; adjusted for age, sex, and time since stroken = 86
Medical sciences (Basel, Switzerland)
SARC-F is associated with handgrip strength in humans (evaluated for osteoporosis) (r = -0.264, p = 0.013).
“SARC-F scores were inversely correlated with handgrip strength (r = -0.264; p = 0.013)”
Humansevaluated for osteoporosisfemalesn = 96
Nutrients
SARC-F is associated with handgrip strength in humans (hospitalized for hip fracture) (r = -0.40).
“The SARC-F score showed a strong negative correlation with the Barthel Index (r = −0.72; p < 0.001) and a moderate correlation with handgrip strength (r = −0.40; p < 0.001).”
Humanshospitalized for hip fracturen = 330
Journal of Health Sciences
SARC-F predicts handgrip strength in humans (older Indian patients with solid tumor) (sensitivity 29.6%, specificity 83.6%).
“SARC-F has a low sensitivity in identifying patients with low handgrip (sensitivity 29.6%, specificity 83.6%, negative predictive value [NPV] 45.4%, positive predictive value [PPV] 72.1%).”
Humansolder Indian patients with solid tumorn = 1,025
Journal of geriatric oncology
SARC-F predicts handgrip strength in humans (outpatient clinic attendees) (AUC = 0.705).
“For HGS and STST, a cut-off of ≥2 yielded the most favorable discrimination (AUC = 0.705 and 0.735, respectively).”
Humansoutpatient clinic attendeesn = 1,355
Nutrition (Burbank, Los Angeles County, Calif.)
SARC-F is associated with handgrip strength in humans (older adults) (ρ = -0.42, p < 0.001).
“and handgrip strength (ρ = -0.42; p < 0.001), supporting convergent validity.”
Humansolder adultsn = 153
Healthcare (Basel, Switzerland)
SARC-F is associated with handgrip strength in humans (p < 0.05).
“SARC-F was significantly correlated with SMM, SMI, HGS, and HGS/SMM in both men and women (p < 0.05).”
Humansn = 205
Scientific reports
SARC-F is associated with handgrip strength in humans.
“In contrast, right-hand grip strength was negatively correlated with SARC-F.”
Humansfemalesn = 19
Journal of bodywork and movement therapies
Physical function
downin humans5upin humans3
8 studies
Physical function
downin humans5upin humans3
SARC-F predicts physical function in humans (community-dwelling older adults) (AUC 0.60 to 0.80).
“Both the SARC-F and SARC-CalF demonstrated acceptable discriminative ability for identifying functional impairment, with area under the curve (AUC) values ranging from 0.60 to 0.80”
Humanscommunity-dwelling older adultsn = 253
Physiotherapy research international : the journal for researchers and clinicians in physical therapy
SARC-F is associated with physical function in humans (adjusted for age and sex).
“Total SARC-F score was consistently associated with muscle strength, physical performance, PROs and DXA components.”
Humansadjusted for age and sex
RMD open
SARC-F is associated with physical function in humans (systemic lupus erythematosus) (p < 0.01).
“Participants with SARC-F ≥4 had worse organ damage and functional measures than those with SARC-F <4 (all p < 0.01).”
Humanssystemic lupus erythematosusfemalesn = 47
Lupus
SARC-F is associated with physical function in humans (cardiovascular disease, SARC-F scores 1-3) (all P < 0.001).
“every 1 point increase in the SARC-F score was associated with lower physical functions such as lower muscle strength and shorter walking distance (all P < 0.001).”
Humanscardiovascular disease, SARC-F scores 1-3n = 1,066
Screening for sarcopenia with SARC-F in older patients hospitalized with cardiovascular disease
European journal of cardiovascular nursing
SARC-F predicts physical function in humans (cancer) (sensitivity: 80%, specificity: 75.7%).
“When low grip strength per FNIH was combined with low SPPB, SARC-F demonstrated high sensitivity (80%) and specificity (75.7%).”
Humanscancern = 80
Journal of geriatric oncology
SARC-F is associated with physical function in humans (patients undergoing hemodialysis).
“The SARC-F and SARC-CalF were both associated with physical function, but not with SMM.”
Humanspatients undergoing hemodialysisn = 30
SARC-F and SARC-CalF are associated with sarcopenia traits in hemodialysis patients
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
SARC-F is associated with physical function in humans.
“Patients in the sarcopenia group had consistently poorer physical function even after adjusting for covariates.”
HumansJapanese hospitalized patients with cardiovascular disease; SARC-F ≥4 versus SARC-F <4, adjusted for covariatesn = 235
Utility of SARC-F for Assessing Physical Function in Elderly Patients With Cardiovascular Disease
Journal of the American Medical Directors Association
SARC-F predicts physical function in humans (score ≥ 4).
“AAH participants with SARC-F scores ≥ 4 had more Instrumental Activity of Daily Living (IADL) deficits, slower chair stand times, lower grip strength, lower short physical performance battery scores”
Humansscore ≥ 4
SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes
Journal of cachexia, sarcopenia and muscle
Frailty
upin humans5OR 12.52
5 studies
Frailty
upin humans5OR 12.52
SARC-F is associated with frailty in humans (standardized OR 12.52, 95% CI: 8.90-23.91, p < 0.001).
“SARC-F was the only variable significantly associated with frailty category (p < 0.001).”
Humansn = 100
Diagnostics (Basel, Switzerland)
SARC-F is associated with frailty in humans (type two intestinal failure) (rs 0.43, p < 0.001).
“SARC-F was correlated with RCFS (rs 0.43, p < 0.001)”
Humanstype two intestinal failuren = 76
Clinical nutrition ESPEN
SARC-F predicts frailty in humans (Emergency Department patients) (AUC 0.92, 95% CI 0.86-0.98, P<0.001).
“SARC-F (AUC 0.92, 95% Confidence Interval (CI) 0.86-0.98, P<0.001; Sensitivity 79.0%, and Specificity 88.9%) performed best for frailty detection as defined by FI”
HumansEmergency Department patients
The journal of nutrition, health & aging
SARC-F predicts frailty in humans (Frailty assessed by the modified Fried scale) (AUC 0.807 (95% CI 0.76–0.84); cutoff ≥2: sensitivity 74.1%, specificity 73.7%).
“SARC-F cut-off ≥2 presented the best balance between sensitivity and specificity (sensitivity: 74.1% vs. specificity: 73.7%) to identify frailty”
HumansFrailty assessed by the modified Fried scale70.7% femalesn = 447
SARC-F Questionnaire Detects Frailty in Older Adults
The journal of nutrition, health & aging
SARC-F predicts frailty in humans (screening).
“Recently, it has also been suggested as a reasonable screening test for frailty.”
Reviewscreening
SARC-F and other screening tests for sarcopenia
Current opinion in clinical nutrition and metabolic care
Grip strength
downin humans3
3 studies
Grip strength
downin humans3
SARC-F is associated with grip strength in kidney transplant patients.
“revealed a negative correlation between SARC-F and total muscle mass, muscle percentage, skeletal muscle mass, skeletal muscle index, grip strength, and walking speed parameters”
Humansin kidney transplant patients
Should we use the SARC-F score in sarcopenia screening in kidney transplant patients?
Irish journal of medical science
SARC-F is associated with grip strength in humans (men 19.0 kg vs 28.0 kg, P<0.001; women 14.0 kg vs 18.0 kg, P<0.001).
“the median HGS was significantly lower in the high-risk SARC-F group for both men (19.0 kg vs 28.0 kg, P<0.001) and women (14.0 kg vs 18.0 kg, P<0.001).”
Humansn = 578
Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia
SARC-F is associated with grip strength in humans (p = 0.013).
“SARC-F with Handgrip strength (p = 0.013)”
Humansn = 100
Geriatrics (Basel, Switzerland)
Length of hospital stay
upin humans3OR 2.34
3 studies
Length of hospital stay
upin humans3OR 2.34
SARC-F predicts length of hospital stay in humans (postoperative lumbar disc herniation surgery; prolonged LOS > 5 days) (aOR 2.79, 95% CI 1.03–7.57).
“and SARC-F (aOR 2.79, 95% CI 1.03–7.57)”
Humanspostoperative lumbar disc herniation surgery; prolonged LOS > 5 daysn = 111
Research SquarePreprint
SARC-F is associated with length of hospital stay in humans (COVID-19) (16.8 h longer hospital stay, p = 0.01).
“One score greater SARC-F was associated with 34% (p = 0.003) greater risk of death, and 16.8 h longer hospital stay (p = 0.01).”
HumansCOVID-19n = 163
BMC geriatrics
SARC-F is associated with length of hospital stay in patients admitted to a hospital with a suspected infarction (OR 2.34, 95% CI 1.09-5.04, p = 0.030).
“Risk of sarcopenia was independently associated with longer LOS (odds ratio, 2.34; 95% CI, 1.09-5.04; p = 0.030)”
Humansin patients admitted to a hospital with a suspected infarction
Nutrients
Depressive symptoms
upin humans2
2 studies
Depressive symptoms
upin humans2
SARC-F is associated with depressive symptoms in humans (Patients on maintenance hemodialysis; multivariable analysis) (B = 0.39 per point, p = 0.009).
“In multivariable analysis, age and SARC-F were independently associated with depressive symptoms (SARC-F: B = 0.39 per point, p = 0.009).”
HumansPatients on maintenance hemodialysis; multivariable analysisn = 95
Medicina (Kaunas, Lithuania)
SARC-F is associated with depressive symptoms in sarcopenic individuals (adjusted P for trend = 0.0028).
“There was a significant dose-dependent association between SARC-F scores and depressive symptoms in sarcopenic individuals (adjusted P for trend = 0.0028).”
Humansin sarcopenic individuals
The Tohoku journal of experimental medicine
SarQoL
downin humans2
2 studies
SarQoL
downin humans2
SARC-F is associated with SarQoL in peritoneal dialysis patients (r=-0.77, p<0.0001).
“Strong inverse relationships were observed between SarQoL and SARC-F scores (r=-0.77, p<0.0001) and age (r=-0.50, p=0.003).”
Humansin peritoneal dialysis patientsn = 32
Nefrologia
SarQoL is associated with SARC-F in humans (probable sarcopenia) (r = - 0.45; p < 0.001).
“SARC-F (r = - 0.45; p < 0.001)”
Humansprobable sarcopenian = 125
BMC geriatrics
Sarcopenic obesity
upin humans2
2 studies
Sarcopenic obesity
upin humans2
SARC-F predicts sarcopenic obesity in humans (hospitalised older adults) (AUC 0.56, 95% CI 0.53–0.60).
“SARC-F showed the highest overall discriminatory ability (AUC 0.56, 95% CI 0.53–0.60), with a cut-off score of 2 providing a reasonable balance between sensitivity and specificity.”
Humanshospitalised older adultsn = 1,233
Research SquarePreprint
SARC-F predicts sarcopenic obesity in humans with high BMI or WC (sensitivity men 5.68%, women 17.82%; specificity men 99.03%, women 94.35%).
“SARC-F (≥4) with high BMI or WC demonstrated low sensitivity (men, 5.68%; women, 17.82%) but high specificity (men, 99.03%; women, 94.35%)”
Humanswith high BMI or WCn = 2,020
Medicina (Kaunas, Lithuania)
All 114Fewer
How this record changed
Summary rewritten as its findings changed.
As it read before
SARC-F predicts mortality in hospitalized adults and cancer cohorts and is associated with muscle strength and physical function in human studies. Sarcopenia detection varies by population and definition. A study of older emergency-department patients with cardiovascular disease finds no mortality association, despite associations with mechanical ventilation and length of stay.
Summary rewritten as its findings changed.
As it read before
In human cohorts, SARC-F associates with walking speed, grip strength, and total muscle mass in kidney transplant recipients, and predicts urinary incontinence in females.
Summary written from the findings.